Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Use of Extended-Duration Thromboprophylaxis

Gynecol Oncol; ePub 2016 Mar 28; Wright, Chen, et al

The use of extended-duration thromboprophylaxis remains low among high-risk cancer patients undergoing surgery despite its demonstration to reduce venous thromboembolic events (VTE) in cancer patients undergoing abdominopelvic surgery. This according to a study of 63,280 patients with colon, ovarian, and uterine cancer who underwent surgery from 2009 to 2013. Researchers found:

• Use of extended-duration prophylaxis increased from 2009 to 2013 from 1.4% to 1.7% for colectomy; 5.9% to 18.3% for ovarian cancer surgery; and 6.3% to 12.2% for hysterectomy for endometrial cancer.

• There was no association between use of extended-duration prophylaxis and reductions in VTE for any of the procedures.

• Extended-duration prophylaxis was associated with an increased risk of adverse postoperative events; OR=2.20 after colectomy, 1.24 after ovarian cancer-directed surgery, and 0.99 for hysterectomy for endometrial cancer.

Citation: Wright JD, Chen L, Jorge S, et al. Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. [Published online ahead of print March 28, 2016]. Gynecol Oncol. doi:http://dx.doi.org/10.1016/j.ygyno.2016.03.023.